(NASDAQ: SVRA) Savara's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 29.34%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.56%.
Savara's revenue in 2026 is $0.On average, 11 Wall Street analysts forecast SVRA's revenue for 2026 to be $376,197,287, with the lowest SVRA revenue forecast at $0, and the highest SVRA revenue forecast at $1,337,544,698. On average, 11 Wall Street analysts forecast SVRA's revenue for 2027 to be $14,775,246,059, with the lowest SVRA revenue forecast at $9,584,298,780, and the highest SVRA revenue forecast at $19,217,497,043.
In 2028, SVRA is forecast to generate $35,189,136,769 in revenue, with the lowest revenue forecast at $28,671,945,093 and the highest revenue forecast at $44,186,230,826.